U.S. Airlines Stock News

Why OSI Systems is in focus today OSI Systems (OSIS) is back on investors' radar after its Security division reported that the Itemiser 4DX and new Itemiser 5X trace detection systems received ECAC/EU G1 approval, meeting stringent European aviation security standards. This certification confirms compliance with European Civil Aviation Conference and European Commission requirements, and ties directly to how the company competes in global aviation security and broader high security screening...

Grand Canyon Education, Inc. has reported its fourth-quarter and full-year 2025 results, showing higher quarterly net income of US$86.73 million and earnings per share growth, alongside issuing detailed 2026 guidance that outlines expected service revenue, operating margins and diluted EPS across each quarter and for the full year. At the same time, the company expanded its stock repurchase authorization to a very large US$2.55 billion program running through March 2027 and elevated...

In February 2026, Federal Realty Investment Trust reported past fourth-quarter and full-year 2025 results showing higher revenue and net income year over year, issued 2026 net income guidance of US$3.90–US$4.00 per diluted share, and its Board declared regular quarterly common and preferred cash dividends payable on April 15, 2026. An interesting wrinkle is that, despite having an authorized buyback in place, Federal Realty did not repurchase any shares in the fourth quarter of 2025,...

Why Dominion Energy’s earnings report is in focus Dominion Energy (D) heads into its February 23, 2026 earnings release with investors watching how the expected $0.66 EPS and revenue figures line up against recently reduced analyst expectations and earlier cautious trading. See our latest analysis for Dominion Energy. Dominion Energy’s recent moves capture that tension, with a 10.67% 1 month share price return and 7.08% 3 month share price return contrasting with a stronger 20.32% 1 year...

Kadant Inc. reported past fourth-quarter 2025 sales of US$286.2 million, up from US$258.03 million a year earlier, with essentially flat quarterly earnings per share, while full-year 2025 sales held around US$1.05 billion and net income and EPS eased compared with the prior year. The company coupled these results with 2026 guidance that points to higher revenue and GAAP EPS and stands to benefit from the recent Supreme Court decision striking down certain tariffs, which may reduce input...

In February 2026, Allstate reported estimated January catastrophe losses of US$175 million tied mainly to Winter Storm Fern and confirmed plans for a US$4.00 billion share repurchase alongside an 8% increase in its common dividend. On the capital side, the company also declared about US$29.30 million in cash dividends on three preferred stock series, underscoring continued commitments to both common and preferred shareholders despite recent weather-related losses. With this backdrop of...

Earlier this week, Merit Medical Systems announced it will report quarterly earnings after Tuesday’s market close, following a prior quarter in which it exceeded analyst revenue expectations and delivered strong organic growth. This combination of an upcoming results release and evidence of recent operational momentum has sharpened investor focus on how effectively Merit is using its capital base despite scale disadvantages and a modest return on invested capital. Next, we’ll examine how the...

IQVIA Holdings (IQV) is back in focus after closing 2025 with revenue and EPS growth near double digits, record R&D Solutions net bookings, and a new obesity research collaboration with Duke Clinical Research Institute. See our latest analysis for IQVIA Holdings. Despite the recent obesity research collaboration and solid year-end results, IQVIA Holdings’ share price has come under pressure, with a 30 day share price return of 29.62% and a 1 year total shareholder return of 13.31%. This...

Earlier this month, Tempus AI launched its new HRD-RNA algorithm for research use, an AI-driven 1,660-gene model designed to better identify homologous recombination deficiency and potential responders to platinum chemotherapy or PARP inhibitors across solid tumors, with clinical availability planned later in 2026. The RNA-based, functional approach may widen the pool of patients who can be matched to targeted therapies compared with traditional DNA “genomic scar” tests, while Tempus also...

Becton Dickinson (BDX) shares are back in focus after the company reported first quarter earnings and reaffirmed its full year 2026 guidance, as well as launching a US$1.6b tender offer for outstanding debt securities. See our latest analysis for Becton Dickinson. At a share price of US$185.39, Becton Dickinson has seen near term momentum pick up, with a 1 day share price return of 1.6% and 7 day share price return of 5.4%, following earnings, buyback activity and the US$1.6b debt tender. Its...

In February 2026, Calix, Inc. announced that Helexon selected its Calix One platform for a multi-year, BEAD-funded rural broadband fiber buildout across Illinois, Indiana, Kentucky, and Michigan, while also rolling out new AI-native platform enhancements and SmartHome features like HomeOfficeIQ and an upgraded Engagement Cloud. Together, these moves show Calix pushing deeper into experience-focused, AI-enabled broadband solutions that can help providers personalize services, streamline...

In February 2026, First Solar, Inc. entered into a new five-year senior unsecured revolving credit facility of US$1.50 billion, replacing its prior secured facility and releasing associated collateral to support working capital and general corporate purposes. The shift from secured to unsecured bank financing signals increased financial flexibility and confidence from lenders, potentially broadening First Solar’s options for funding expansion and managing trade-related cost pressures. With...

If you are wondering whether Moderna's current share price still reflects its long term potential, you are not alone. This article focuses squarely on what the stock might be worth based on different valuation lenses. Moderna's share price closed at US$49.87, with returns of 18.1% over the last 7 days, 2.4% over 30 days and 61.6% year to date, while the 1 year return is 40.4% and the 3 and 5 year returns are negative at 64.2% and 67.8% respectively. Recent headlines have continued to focus...

Aehr Test Systems previously announced that it received a firm production order from a world-leading hyperscaler to test high-performance AI accelerator chips, with the contract expected to meaningfully influence its revenue and earnings as early as the second quarter of 2026. This deal highlights Aehr’s role as a key enabling partner in the complex testing demands of next-generation AI data center infrastructure. Next, we’ll examine how this hyperscaler AI chip-testing contract shapes Aehr...

Why Blue Bird (BLBD) is on investors’ radar now Blue Bird (BLBD) has drawn fresh attention after recent share price moves that leave it trading around $61. This has prompted investors to reassess the school bus manufacturer’s value, growth profile, and risk-reward trade off. See our latest analysis for Blue Bird. Recent moves to around $61 come after a 23.06% 1 month share price return and a 30.45% year to date share price return, alongside a 73.89% 1 year total shareholder return. This...

On February 15, 2026, AtaiBeckley Inc. announced that experienced biopharma finance executive Michael Faerm will become Chief Financial Officer and principal financial officer on March 9, 2026, while current CFO Anne Johnson will shift to Chief Accounting Officer and remain principal accounting officer. This leadership reshuffle pairs Faerm’s capital-markets and operating background with Johnson’s continuity in accounting oversight, potentially sharpening AtaiBeckley’s financial execution as...

Dyne Therapeutics (DYN) is back in focus after highlighting five upcoming presentations at the 2026 Muscular Dystrophy Association conference and securing Orphan Drug designation in Japan for its myotonic dystrophy type 1 therapy. See our latest analysis for Dyne Therapeutics. Despite the recent regulatory and conference catalysts, Dyne Therapeutics’ short term momentum has cooled, with a 30 day share price return decline of 17.33% and a 90 day decline of 31.33%, even as the 1 year total...

Ryan Specialty Holdings (RYAN) just paired a mixed fourth quarter earnings report with an 8.3% dividend increase and a new US$300 million buyback plan, a combination that quickly drew fresh attention to the stock. See our latest analysis for Ryan Specialty Holdings. The mixed fourth quarter numbers, alongside the richer dividend and US$300 million buyback plan, come after a sharp reset in sentiment, with a 30 day share price return showing a 17.4% decline and a 1 year total shareholder return...

In February 2026, UL Solutions Inc. reported Q4 2025 sales of US$789 million and full‑year 2025 sales of US$3.05 billion, alongside essentially flat annual net income of US$325 million and a quarterly GAAP EPS decline versus the prior year. The company coupled this performance with an 11.5% dividend increase and the planned sale of its employee health and safety software business, indicating a tighter focus on higher‑growth core services and software offerings. Next, we’ll explore how the...

In February 2026, Caesars Entertainment reported fourth-quarter and full-year 2025 results showing modest revenue growth to US$2.92 billion in the quarter and US$11.49 billion for the year, but a wider net loss of US$250 million in Q4 and US$502 million for 2025 alongside an earnings miss. At the same time, Caesars highlighted strong momentum in its higher-growth digital betting operations and continued investment in property upgrades, while also rolling out its first in-house developed...

What Crescent Energy’s Recent Share Move Signals Crescent Energy (CRGY) has drawn fresh attention after a strong month, with the stock closing at US$10.71 and posting a return of about 23% over that period. That move comes alongside reported annual revenue of US$3.59b and net income of US$23.53m. This gives investors a concrete snapshot of the company’s current earnings base. See our latest analysis for Crescent Energy. While Crescent Energy’s 22.96% 1 month share price return and 16.92% 3...

In recent years, Powell Industries has evolved from a small Houston manufacturer into a global provider of electrical systems, supported by strong demand evidenced by average backlog growth of 15.4% and annual earnings per share growth of 58.2% over the past two years. At the company’s annual meeting on February 18, 2026, shareholders reinforced governance continuity by re-electing two directors, approving executive pay, and appointing a new audit committee chair, aligning board oversight...

California Water Service Group recently outlined plans to invest about US$2.06 billion between 2025 and 2027 to upgrade and modernize its water infrastructure, while analysts slightly lifted their 2026 earnings-per-share expectations. At the same time, the company highlighted its broader role in communities by donating nearly US$1.9 million in 2025 to local organizations, fire departments, and students, underscoring a business model that ties long-term capital spending to social...

Edison International recently reported full-year 2025 results, with sales rising to US$19,317 million and net income to US$4.46 billion, alongside sharply higher earnings per share and an affirmed quarterly dividend of US$0.8775. These results were heavily influenced by favorable regulatory decisions and wildfire-related settlement recoveries, which significantly boosted reported profitability and underlined progress on grid hardening and wildfire mitigation. We’ll now examine how this...